Fig 2: Targeting performance and mechanism of nanosystems to infected cells and intracellular MRSA. (A-B) Cellular uptake of PCN-224, GaPR-PCN, and HA-GaPR-PCN by sterile and MRSA-infected RAW264.7 (A) and MAC-T cells (B) (n=3). (C, D) Cellular uptake inhibition of Lev-GaPR-PCN by RAW 264.7 after 2 h of co-incubation of CPZ (chlorpromazine), CYT (Cytochalasin), AMI (amilori) and anti-CD163 and anti-LRP1. E-F) Cellular uptake of Lev-GaPR-PCN by sterile and MRSA-infected RAW 264.7 cells when removing Hpx (E) and Hpg (F) by the fresh culture medium and spiked Hpg and Hpx into old culture medium. Replaced culture medium (-), without replacing the medium (+). (G) Intracellular co-localization of PCN-224 and GaPR-PCN with MRSA determined by CLSM. Scale bars, 10 μm. (H) Continuous confocal fluorescence microscope images of HA-GaPR-PCN transport into MRSA infected RAW 264.7 cells during 125-145 min. Scale bars, 5 μm. (I) Intracellular co-localization of GaPR-PCN with early endosomes, late endosome, Golgi apparatus, and lysosome. Scale bars, 10 μm.